|Articles|November 17, 0001

B&L buys Pharmos piece; deal could hit $49 million

B&L buys Pharmos piece; deal could hit $49 millionRochester, NY-Bausch & Lomb has acquired the rights to theloteprednol etabonate ophthalmic business of Pharmos Corp. for a price thatmight reach $49 million.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Latest CME